Progesterone Capsule
Product Images NDC 51407-980

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Progesterone (NDC 51407-980). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-980-01ol (Progesterone 100 mg)

51407-980-01ol (Progesterone 100 mg)
This text includes information about Progesterone Capsules with a dosage of 100mg micronized progesterone per capsule. It provides instructions on usage, storage, and precautions, such as keeping out of reach of children and protecting from moisture. The product should not be used by individuals allergic to peanuts. The packaging includes a link for obtaining patient information online. The product is marketed by GSMS, Inc. in Camarillo, California, USA.*
FDA Label Image

51407-981-01ol (Progesterone 200 mg)

51407-981-01ol (Progesterone 200 mg)
Each capsule of NDC 51407-981-01 contains 200 mg of micronized progesterone. This medication is typically used as prescribed by the healthcare provider, with the specific dosage instructions provided in the package insert. It is important to carefully read the accompanying directions before use. Remember to store the capsules in a tightly-sealed, light-resistant container, away from moisture, and at a temperature between 20°C - 25°C (68°F - 77°F). This product should not be used if allergic to peanuts, and should be kept out of the reach of children. Pharmacists should provide patient information along with each dispensed package. More information can be accessed at https://gsms.us/.*
FDA Label Image

Graph1 (Figure01)

Graph1 (Figure01)
This data appears to show a comparison between the effects of conjugated estrogens alone, conjugated estrogens plus micronized progesterone in a cyclical manner, and a placebo over a period of 36 months. The table indicates the number of patients (n) remaining in each group at intervals of 0, 12, 24, and 36 months. This information may be useful for evaluating the efficacy and tolerability of these medications over an extended period.*
FDA Label Image

Chemical Structure (Structure01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.